AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28525512 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg at the end of surgery and then every 12 hours for 3 days)
Number of subjects: 620
Study 28525512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 620
Study 28525512 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 620
Study 28525512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 25496767 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical cystectomy (RARC) with PLND
Number of subjects: 118
Study 25496767 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC) with PLND
Number of subjects: 118
Study 25496767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RARC and ORC
Number of subjects: 118
Study 25496767 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 118
Study 23691828 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-column (with long line length) layout
Number of subjects: 210
Study 23691828 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicolumn setting (with medium or short line length)
Number of subjects: 210
Study 23691828 — intervention group
Group type: COMPARATOR
Intervention: Interline spacing
Number of subjects: 210
Study 21642242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise stress test after intermittent upper arm ischaemia (EST‐2)
Number of subjects: 20
Study 21642242 — intervention group
Group type: COMPARATOR
Intervention: Maximal exercise stress test only (EST‐1)
Number of subjects: 20
Study 19096945 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of sterile water
Number of subjects: 100
Study 19096945 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 100
Study 16449048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health workers (LHWs) involved in TB control activities on farms
Number of subjects: 0
Study 16449048 — intervention group
Group type: COMPARATOR
Intervention: Current local tuberculosis control programme
Number of subjects: 0
Study 15504182 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 7.5 mg with sufentanil 5 microg
Number of subjects: 50
Study 15504182 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 15 mg
Number of subjects: 50
Study 11783100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 34
Study 11783100 — intervention group
Group type: COMPARATOR
Intervention: Kytril
Number of subjects: 34
Study 9259608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemical method (ELISA) for detecting P. carinii antibodies
Number of subjects: 0
Study 9259608 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown rat (Rattus norvegicus)
Number of subjects: 0
Study 9259608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bank vole (Clethrionomys glareolus)
Number of subjects: 0
Study 9259608 — intervention group
Group type: EXPERIMENTAL
Intervention: European water voles (Arvicola terrestris) and field voles (Microtus arvalis)
Number of subjects: 0
Study 8388403 — intervention group
Group type: EXPERIMENTAL
Intervention: ile12-ANP (1.5 pmol/kg/min)
Number of subjects: 8
Study 8388403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30972018 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg fasudil
Number of subjects: 120
Study 30972018 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fasudil
Number of subjects: 120
Study 30972018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30972018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (30 mg or 60 mg)
Number of subjects: 120
Study 30049304 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin oral tablet (0.6 mg; 0.2 mg × 3) under fed conditions
Number of subjects: 104
Study 30049304 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin oral tablet (0.6 mg; 0.2 mg × 3) under fasted conditions
Number of subjects: 104
Study 26723860 — intervention group
Group type: EXPERIMENTAL
Intervention: K2/Apex hip system
Number of subjects: 3
Study 24351876 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanuts with a variety of flavors (n = 50)
Number of subjects: 151
Study 24351876 — intervention group
Group type: COMPARATOR
Intervention: Peanuts with a single flavor (n = 25-26/group)
Number of subjects: 151
Study 24351876 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants at greater risk of cardiovascular disease
Number of subjects: 151
Study 24351876 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanuts with any flavoring
Number of subjects: 151
Study 23216861 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Community Telerehabilitation Intervention (ACTIV)
Number of subjects: 0
Study 23216861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19914369 — intervention group
Group type: EXPERIMENTAL
Intervention: EG 500 (500 mg of Campomanesia xanthocarpa)
Number of subjects: 33
Study 19914369 — intervention group
Group type: EXPERIMENTAL
Intervention: EG 250 (250 mg of Campomanesia xanthocarpa)
Number of subjects: 33
Study 19914369 — intervention group
Group type: COMPARATOR
Intervention: CG (placebo capsules)
Number of subjects: 33
Study 18715435 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 40
Study 18715435 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 40
Study 16427526 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (PHYSO)
Number of subjects: 40
Study 16427526 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 40
Study 12663362 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured replacement insoles in football boots
Number of subjects: 17
Study 12663362 — intervention group
Group type: COMPARATOR
Intervention: Conventional smooth insoles in football boots
Number of subjects: 17
Study 10066008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine combined with exposure
Number of subjects: 76
Study 10066008 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication plus exposure
Number of subjects: 76
Study 10066008 — intervention group
Group type: COMPARATOR
Intervention: Psychological panic management plus exposure
Number of subjects: 76
Study 10066008 — intervention group
Group type: COMPARATOR
Intervention: Exposure alone
Number of subjects: 76
Study 10066008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus exposure
Number of subjects: 76
Study 10066008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 76
Study 8952328 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Estimated Ecological Daily Intake (EEDI) method for estimating daily intake of food contaminants and additives.
Number of subjects: 159
Study 8952328 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved EEDI method incorporating contamination levels of foodstuffs.
Number of subjects: 159
Study 8952328 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved EEDI method for estimating daily intake of environmental contaminants.
Number of subjects: 159
Study 1802182 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine connection shield (Group 2, n = 22)
Number of subjects: 35
Study 1802182 — intervention group
Group type: COMPARATOR
Intervention: Standard management (Group 1, n = 25)
Number of subjects: 35
Study 6478471 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol, 50 mg
Number of subjects: 12
Study 6478471 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 10 mg
Number of subjects: 12
Study 30916625 — intervention group
Group type: EXPERIMENTAL
Intervention: Single use polyvinylchloride catheters
Number of subjects: 75
Study 30916625 — intervention group
Group type: COMPARATOR
Intervention: Reused polyvinylchloride catheters
Number of subjects: 75
Study 30101439 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg TFV film
Number of subjects: 78
Study 30101439 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg TFV film
Number of subjects: 78
Study 30101439 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV 1% gel
Number of subjects: 78
Study 30101439 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 78
Study 30101439 — intervention group
Group type: COMPARATOR
Intervention: Placebo film
Number of subjects: 78
Study 30101439 — intervention group
Group type: EXPERIMENTAL
Intervention: Film users
Number of subjects: 78
Study 27371905 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 27
Study 27371905 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 25439165 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training for 3 weeks
Number of subjects: 18
Study 25439165 — intervention group
Group type: COMPARATOR
Intervention: Placebo WBV (sham WBV) for 3 weeks
Number of subjects: 18
Study 23006462 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment for a variable period of 1-12 years
Number of subjects: 40
Study 23006462 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 40
Study 23006462 — intervention group
Group type: COMPARATOR
Intervention: Fulminant hepatic failure (FHF) without liver transplantation
Number of subjects: 40
Study 23006462 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality during the study period
Number of subjects: 40
Study 19947406 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave therapy included in rehabilitative program
Number of subjects: 49
Study 17179770 — intervention group
Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFAs) - 2 capsules containing 1 g of fish oil 3 times daily (n = 60)
Number of subjects: 122
Study 17179770 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 1 g of paraffin oil capsules (n = 62)
Number of subjects: 122
Study 17179770 — intervention group
Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFAs) - open-label phase
Number of subjects: 122
Study 17179770 — intervention group
Group type: COMPARATOR
Intervention: Placebo - open-label phase
Number of subjects: 122
Study 17179770 — intervention group
Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 122
Study 17179770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 17179770 — intervention group
Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFAs) - patients with baseline TG levels >10 g/L
Number of subjects: 122
Study 17179770 — intervention group
Group type: COMPARATOR
Intervention: N-3 polyunsaturated fatty acids (PUFAs) vs. Placebo
Number of subjects: 122
Study 15123223 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SLM/FP) 50 microg and 500 microg Diskus, 1 inhalation twice daily
Number of subjects: 80
Study 15123223 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (THEO) plus fluticasone propionate (FP) 500 microg Diskus, 1 inhalation twice daily
Number of subjects: 80
Study 11241808 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D‐echo
Number of subjects: 50
Study 11241808 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 50
Study 9678714 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP, 900-600 mg/m2 orally)
Number of subjects: 166
Study 9678714 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose prednisolone (2 mg/kg/day orally)
Number of subjects: 166
Study 9678714 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP)
Number of subjects: 166
Study 8034783 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.4% zinc sulphate and 0.15% triclosan (mouthrinse 1)
Number of subjects: 0
Study 8034783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 0
Study 8034783 — intervention group
Group type: COMPARATOR
Intervention: Negative control mouthrinse
Number of subjects: 0
Study 2660553 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 667
Study 2660553 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 667
Study 2660553 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate and Cimetidine
Number of subjects: 667
Study 4913624 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine acid phosphate (1, 10, 40, and 80 mug/kg/hr)
Number of subjects: 6
Study 4913624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.15, 1.5, 6.0, and 12.0 mug/kg/hr)
Number of subjects: 6
Study 4913624 — intervention group
Group type: COMPARATOR
Intervention: Histamine acid phosphate and Pentagastrin (comparison)
Number of subjects: 6
Study 31764395 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aids
Number of subjects: 6376
Study 31764395 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-clinician communication
Number of subjects: 6376
Study 31764395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-facilitated communication interventions
Number of subjects: 6376
Study 31477168 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐DM1, lapatinib, and nab‐paclitaxel
Number of subjects: 30
Study 31477168 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab, pertuzumab, and paclitaxel
Number of subjects: 30
Study 31477168 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐DM1, lapatinib, and nab‐paclitaxel (in ER-positive subset)
Number of subjects: 30
Study 31477168 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab, pertuzumab, and paclitaxel (in ER-positive subset)
Number of subjects: 30
Study 28000311 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG) 0.4 g/kg/week for 5 weeks
Number of subjects: 20
Study 28000311 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days
Number of subjects: 20
Study 26555352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intradermal TIV
Number of subjects: 155
Study 23820880 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain (CKC) exercises
Number of subjects: 32
Study 23820880 — intervention group
Group type: COMPARATOR
Intervention: Closed Kinetic Chain (CKC) exercises with additional hip strengthening exercises (Control group)
Number of subjects: 32
Study 21573899 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage of the wound
Number of subjects: 803
Study 21573899 — intervention group
Group type: COMPARATOR
Intervention: No drainage of the wound
Number of subjects: 803
Study 19500421 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Care Program for Dementia (SCPD)
Number of subjects: 6
Study 19500421 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 6
Study 16924032 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF BACE1 activity in Alzheimer disease (AD)
Number of subjects: 68
Study 16924032 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF BACE1 activity in sporadic CJD
Number of subjects: 68
Study 15043759 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 100
Study 15043759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12054149 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl citrate (SLFC)
Number of subjects: 11
Study 11326965 — intervention group
Group type: EXPERIMENTAL
Intervention: NO inhalation (10 ppm for 30 min)
Number of subjects: 65
Study 11326965 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg, tid) in addition to conventional therapy
Number of subjects: 65
Study 11326965 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (oxygen, intravenous furosemide, aminophylline, dexamethasone)
Number of subjects: 65
Study 7827638 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 (0.05 mg/24 h)
Number of subjects: 8
Study 7827638 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 (0.05 mg/24 h) + Nomegestrol acetate (5 mg/24 h)
Number of subjects: 8
Study 7827638 — intervention group
Group type: COMPARATOR
Intervention: Baseline (before treatment)
Number of subjects: 8
Study 7827638 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 treatment (after 2 weeks)
Number of subjects: 8
Study 7827638 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 treatment (3rd month)
Number of subjects: 8
Study 3287675 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg or 1,200 mg daily for a mean duration of 35 months
Number of subjects: 120
Study 3287675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not taking aspirin)
Number of subjects: 120
Study 49474 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 36
Study 49474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin
Number of subjects: 36
Study 49474 — intervention group
Group type: COMPARATOR
Intervention: Wheat fibre
Number of subjects: 36
Study 31077250 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and metoprolol
Number of subjects: 38
Study 31077250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30303905 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide 20 mg/d for 5 days
Number of subjects: 118
Study 30303905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 26049866 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg cranberry powder (Flowens™)
Number of subjects: 124
Study 26049866 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg cranberry powder (Flowens™)
Number of subjects: 124
Study 26049866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 23224838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (dietary intervention)
Number of subjects: 0
Study 23224838 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided)
Number of subjects: 0
Study 22271481 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) for 5 years
Number of subjects: 3714
Study 22271481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) for 2 years followed by Anastrozole (ANA) for 3 years
Number of subjects: 3714
Study 19908172 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim recovery session (SRS) (20x100 m at 90% of 1 km time trial speed)
Number of subjects: 9
Study 19908172 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery session (PRS)
Number of subjects: 9
Study 19908172 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim recovery session (SRS)
Number of subjects: 9
Study 19908172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 9
Study 17347010 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 130
Study 17347010 — intervention group
Group type: COMPARATOR
Intervention: Control group (normative data)
Number of subjects: 130
Study 17347010 — intervention group
Group type: COMPARATOR
Intervention: Before GH replacement therapy
Number of subjects: 130
Study 17347010 — intervention group
Group type: EXPERIMENTAL
Intervention: During GH replacement therapy
Number of subjects: 130
Study 16342340 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia
Number of subjects: 156
Study 16342340 — intervention group
Group type: COMPARATOR
Intervention: Tepid blood cardioplegia
Number of subjects: 156
Study 16342340 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 156
Study 11896309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentastarch
Number of subjects: 0
Study 11896309 — intervention group
Group type: COMPARATOR
Intervention: Hetastarch
Number of subjects: 0
Study 10610046 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal irradiation
Number of subjects: 50
Study 8951516 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted procedure (LAP)
Number of subjects: 30
Study 8951516 — intervention group
Group type: COMPARATOR
Intervention: Standard midline incision (SMI)
Number of subjects: 30
Study 2275936 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival gentamicin
Number of subjects: 121
Study 2275936 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival cefuroxime
Number of subjects: 121
Study 7304259 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 30
Study 7304259 — intervention group
Group type: COMPARATOR
Intervention: Metrizoate
Number of subjects: 30
Study 30845349 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhamnose
Number of subjects: 0
Study 28992377 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ABM training
Number of subjects: 60
Study 28992377 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 60
Study 24045634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lode stationary bicycle ergometer (SBE)
Number of subjects: 10
Study 24045634 — intervention group
Group type: COMPARATOR
Intervention: PowerTap Pro+ (BPT)
Number of subjects: 10
Study 25108708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime before 8:30 pm (n=14)
Number of subjects: 20
Study 25108708 — intervention group
Group type: COMPARATOR
Intervention: Bedtime after 8:30 pm (n=6)
Number of subjects: 20
Study 25108708 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants dependent on nursing care for nighttime ADLs (n=9)
Number of subjects: 20
Study 22007933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined planning and self-efficacy intervention
Number of subjects: 883
Study 22007933 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 883
Study 20231115 — intervention group
Group type: EXPERIMENTAL
Intervention: High preexposure condition (10 clips showing strong pain)
Number of subjects: 0
Study 20231115 — intervention group
Group type: COMPARATOR
Intervention: No-exposure control
Number of subjects: 0
Study 16958129 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session depression intervention
Number of subjects: 145
Study 16958129 — intervention group
Group type: COMPARATOR
Intervention: Measurement-only condition (Control)
Number of subjects: 145